SpringWorks Therapeutics — Technical Presentation (September 2022)
17 slides from SpringWorks Therapeutics's technical presentation, Sep 12, 2022
Slide 1: DeFi: A Phase 3 Trial of Nirogacestat for Progressing Desmoid Tumors
DeFi: A Phase 3 Trial of Nirogacestat for Progressing Desmoid Tumors (DT) Bernd Kasper , Ravin Ratan, Thierry Alcindor, Patrick Schöffski, Winette T. van der Graaf, Breelyn A. Wilky, Richard F. Riedel, Allison Lim, L. Mary Smith, Stephanie Moody, Steven Attia, Sant Chawla, Gina D’Amato, Noah Federma
Slide 2: Declaration of Interests
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use . Declaration of Interests ▪ Bernd Kasper’s declaration of interests : ▪ Financial interests ▪ Ayala (advisory board, personal), Bayer (advisory board, personal), Blueprint, (advisory boar
Slide 3: Gamma Secretase Inhibition in Desmoid Tumors
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use . Gamma Secretase Inhibition in Desmoid Tumors ▪ Desmoid tumors (DT) are rare, locally aggressive, and invasive soft - tissue tumors that are challenging to manage due to variable presenta
Slide 4: DeFi: Phase 3 Study Design
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use . Nirogacestat 150 mg BID Placebo BID ▪ Histologically confirmed DT with progressive disease per RECIST v1.1 a ▪ Treatment - naïve with DT not amenable to surgery, or ▪ Refractory or recur
Slide 5: Baseline Demographics and Characteristics
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use . Baseline Demographics and Characteristics a Evaluable samples not available for all patients. Samples were analyzed for 51 and 53 patients in the nirogacestat and placeb o a rms, respect
Slide 6: Significantly Reduced Risk of Disease Progression
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use . Nirogacestat Significantly Reduced Risk of Disease Progression Median follow - up time was 19.2 months for nirogacestat and 10.9 months for placebo. NE, not estimable. No. of Patients No
Slide 7: PFS Benefit With Nirogacestat Was Observed Across Prespecified Subgroups
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use . PFS Benefit With Nirogacestat Was Observed Across Prespecified Subgroups PFS, progression - free survival; TKI, tyrosine kinase inhibitor. Kasper et al. DeFi Phase 3 in Adult Desmoid Tum
Slide 8: Objective Response Rate by Blinded Independent Central Review
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use . Objective Response Rate by Blinded Independent Central Review a Duration of objective response was defined as duration in months from the time CR or PR (which ever came first) was met un
Slide 9: Nirogacestat Treatment Resulted in Substantial Reductions in Tumor Size
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use . Placebo * Nirogacestat Nirogacestat Treatment Resulted in Substantial Reductions in Tumor Size Change in tumor size, % *Patient had a complete resolution of the target lesion but still h
Slide 10: Significantly Reduced Pain Severity Compared With Placebo
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use . Nirogacestat Significantly Reduced Pain Severity Compared With Placebo Mean (SD ) baseline scores: nirogacestat, 3.2 (3.26 ) ; placebo, 3.3 (3.31 ). Differences at Cycle 10 were statisti
Slide 11: Significantly Reduced DT-Specific Symptom Severity
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use . Nirogacestat Significantly Reduced DT - Specific Symptom Severity Mean (SD) baseline scores: nirogacestat, 3.4 (2.34); placebo, 3.5 (2.57). Differences at Cycle 10 were statistically sig
Slide 12: Significantly Improved Physical/Role Functioning and QoL
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use . Nirogacestat Significantly Improved Physical/Role Functioning and QoL Mean (SD) baseline scores: nirogacestat, 2.8 (1.14); placebo, 2.7 (1.24). Differences at Cycle 10 were statistically
Slide 13: Safety Profile
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use . Nirogacestat Safety Profile a Death due to sepsis. b TEAEs leading to discontinuations in ≥1 patient include gastrointestinal disorders (n=5 [4%]), ovarian dysfunction (n=4 [3%]) , a lan
Slide 14: Frequency and Resolution of Ovarian Dysfunction Observed With Nirogacestat
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use . Frequency and Resolution of Ovarian Dysfunction Observed With Nirogacestat a OD among women of childbearing potential was defined by investigators who reported the MedDRA Preferred Terms
Slide 15: Conclusions
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use . ▪ DeFi represents the largest and most rigorous randomized controlled trial conducted to date in DT – DeFi is also the first Phase 3, randomized, controlled trial to demonstrate clinical
Slide 16: Acknowledgments
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use . Acknowledgments ▪ We thank the DeFi trial participants, their families, and trial personnel ▪ We thank these DeFi Principal Investigators for their contributions to participant enrollm
Slide 17: European Society for Medical Oncology (ESMO) contact
European Society for Medical Oncology (ESMO) Via Ginevra 4, CH - 6900 Lugano T. +41 (0)91 973 19 00 esmo@esmo.org esmo.org
SpringWorks Therapeutics — Technical Presentation (September 2022) on 6ix